South Rampart Pharma Revenue and Competitors

South Rampart Pharma has an asset in Ph 1 trials to improve the lives of people suffering from acute, chronic, and neuropathic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in medicines.\n\nThe safe treatment of pain is one of the most prevalent and costly public health issues worldwide. In the U.S., pain affects more adults than diabetes and cancer combined and costs the healthcare system an estimated $635 billion each year. Current medications are either highly addictive or cause harm to the liver and kidney. There is a great unmet need for new safe, effective and non-opioid pain medications.\n\nSouth Rampart Pharma is a clinical-stage life science company focused on pain relief innovation. It is developing and commercializing a novel non-opioid small molecule to treat acute, neuropathic, and chronic pain. Its lead asset, SRP-3D (DA), is currently in Phase 1 clinical trials. Funded in part by an NIH STTR ‘Fast-Track’ grant, the company’s composition of matter IP covers its proprietary compounds that reduce pain and fever in pre-clinical studies. It lacks the liver and kidney toxicities associated with current analgesics, enabling patients to overcome many risks related to current medications and pain medicines. Benefits of this small molecule technology include the known mechanisms of action (MOA) for the absent toxicities and the central MOA for analgesia (pain relief), de-risking the clinical development.